Kura Oncology is trading 7.69% down at $9.12 amid weak overnight markets; available evidence does not identify a company-specific catalyst. - U.S. indices and futures fell amid geopolitical tensions and concerns about technology spending. Biotech’s pre-market strength runs counter to the stock’s move. - The investor-relations page lists October 13, 2026, as its latest press release; a market update likewise reported no company-specific catalyst.